Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20264184 | 0.90 | NPC1 (0.41) | NPC1HDAC4HDAC6BDKRB1MAPK14 | |
| SCHEMBL20280053 | 0.88 | NPC1 (0.39) | NPC1HDAC4HDAC6BDKRB1MAPK14 | |
| SCHEMBL20264276 | 0.87 | NPC1 (0.40) | NPC1HDAC4HDAC6BDKRB1MAPK14 | |
| SCHEMBL20286415 | 0.87 | NPC1 (0.44) | NPC1XIAPTP53 | |
| SCHEMBL20263801 | 0.87 | NPC1 (0.44) | NPC1XIAPTP53 | |
| SCHEMBL20264284 | 0.86 | HDAC4 (0.38) | HDAC4HDAC6BDKRB1MAPK14GPR119 | |
| SCHEMBL20263961 | 0.86 | NPC1 (0.44) | NPC1HDAC4HDAC6XIAPTP53 | |
| SCHEMBL20264144 | 0.86 | XIAP (0.46) | NPC1XIAPTP53SRC | |
| SCHEMBL20264246 | 0.85 | NPC1 (0.45) | NPC1HDAC6XIAPTP53SRC | |
| SCHEMBL20264149 | 0.85 | NPC1 (0.43) | NPC1HDAC4HDAC6XIAPTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472341-B2 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | APEIRON BIOLOGICS AG (AT) | 2019-11-12 | — | — | US | disclosed |
| US-10472341-B2 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | APEIRON BIOLOGICS AG (AT) | 2019-11-12 | — | — | US | disclosed |
| EP-3265463-B1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | APEIRON BIOLOGICS AG (AT) | 2018-12-19 | — | — | EP | disclosed |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | APEIRON BIOLOGICS GMBH (AT) | 2018-06-21 | — | — | US | disclosed |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | APEIRON BIOLOGICS GMBH (AT) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472341-B2 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | CCNT2, HRH4, HRH3 | NPC1 563/4885HDAC4 904/4885HDAC6 2573/4885 |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | CCNT2, HRH4, HRH3 | NPC1 563/4885HDAC4 904/4885HDAC6 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.